Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ITM Radiopharma

Request full access

Radioisotopes and radiopharmaceuticals for cancer treatment

Garching bei München, GermanyFounded 2004Biotech & Life Sciences

About ITM Radiopharma

ITM Isotope Technologies Munich (ITM Radiopharma) is a German radiopharmaceutical company headquartered in Garching near Munich that produces medical radioisotopes and develops targeted radiopharmaceutical therapies and diagnostics for cancer. Founded in 2004, the company has grown from an isotope manufacturer into a vertically integrated radiopharmaceutical business with a global distribution network spanning more than 65 countries.

ITM is a leading producer of therapeutic radioisotopes, most notably high-purity non-carrier-added lutetium-177, which it supplies to pharmaceutical companies, radiopharmacies and hospitals for both approved and investigational targeted radionuclide therapies. It is expanding into further isotopes including actinium-225 and terbium-161, supported by its NOVA production facility in Germany and the Actineer joint venture with Canadian Nuclear Laboratories, and it also provides radiolabelling equipment such as synthesizers and quality control systems.

Its drug pipeline focuses on precision oncology using the theranostic approach, in which a targeting molecule carries a radioisotope directly to tumour cells for imaging or treatment while sparing surrounding tissue. The lead candidate, ITM-11 (lutetium-177 edotreotide), has completed Phase 3 development for gastroenteropancreatic neuroendocrine tumours, and further programmes address glioblastoma, prostate cancer and other solid tumours.

The company generates revenue mainly from the sale of radioisotopes and related products to pharmaceutical partners and healthcare providers, alongside its proprietary drug development pipeline.

Source: Dealroom company data

ITM Radiopharma in the Garching bei München ecosystem

Live from Dealroom

The ITM Radiopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Petrichor

Series B and later10 investors entered at this stage

Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 8 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$40M

14 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See ITM Radiopharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.